Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial

Claire A Surr; Rebecca E A Walwyn; Amanda Lilley-Kelly; Robert Cicero; David Meads; Clive Ballard; Kayleigh Burton; Lynn Chenoweth; Anne Corbett; Byron Creese; Murna Downs; Amanda J Farrin; Jane Fossey; Lucy Garrod; Elizabeth H Graham; Alys Griffiths; Ivana Holloway; Sharon Jones; Baber Malik; Najma Siddiqi; Louise Robinson; Graham Stokes; Daphne Wallace

doi:10.1186/s13063-016-1416-z

Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial

Claire A Surr, Rebecca E A Walwyn, Amanda Lilley-Kelly, Robert Cicero, David Meads, Clive Ballard, Kayleigh Burton, Lynn Chenoweth, Anne Corbett, Byron Creese, Murna Downs, Amanda J Farrin, Jane Fossey, Lucy Garrod, Elizabeth H Graham, Alys Griffiths, Ivana Holloway, Sharon Jones, Baber Malik, Najma SiddiqiLouise Robinson, Graham Stokes, Daphne Wallace

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

189 Downloads (Pure)

Abstract

BACKGROUND: Up to 90 % of people living with dementia in care homes experience one or more behaviours that staff may describe as challenging to support (BSC). Of these agitation is the most common and difficult to manage. The presence of agitation is associated with fewer visits from relatives, poorer quality of life and social isolation. It is recommended that agitation is treated through psychosocial interventions. Dementia Care Mapping™ (DCM™) is an established, widely used observational tool and practice development cycle, for ensuring a systematic approach to providing person-centred care. There is a body of practice-based literature and experience to suggests that DCM™ is potentially effective but limited robust evidence for its effectiveness, and no examination of its cost-effectiveness, as a UK health care intervention. Therefore, a definitive randomised controlled trial (RCT) of DCM™ in the UK is urgently needed.

METHODS/DESIGN: A pragmatic, multi-centre, cluster-randomised controlled trial of Dementia Care Mapping (DCM™) plus Usual Care (UC) versus UC alone, where UC is the normal care delivered within the care home following a minimum level of dementia awareness training. The trial will take place in residential, nursing and dementia-specialist care homes across West Yorkshire, Oxfordshire and London, with residents with dementia. A random sample of 50 care homes will be selected within which a minimum of 750 residents will be registered. Care homes will be randomised in an allocation ratio of 3:2 to receive either intervention or control. Outcome measures will be obtained at 6 and 16 months following randomisation. The primary outcome is agitation as measured by the Cohen-Mansfield Agitation Inventory, at 16 months post randomisation. Key secondary outcomes are other BSC and quality of life. There will be an integral cost-effectiveness analysis and a process evaluation.

DISCUSSION: The protocol was refined following a pilot of trial procedures. Changes include replacement of a questionnaire, whose wording caused some residents distress, to an adapted version specifically designed for use in care homes, a change to the randomisation stratification factors, adaption in how the staff measures are collected to encourage greater compliance, and additional reminders to intervention homes of when mapping cycles are due, via text message.

TRIAL REGISTRATION: Current Controlled Trials ISRCTN82288852 . Registered on 16 January 2014. Full protocol version and date: v7.1: 18 December 2015.

Original language	English
Pages (from-to)	300
Journal	Trials
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s13063-016-1416-z
Publication status	Published - 24 Jun 2016

Access to Document

10.1186/s13063-016-1416-zLicence: CC BY

Evaluating the effectiveness_SURR_Accepted 24 May2016_GOLD VoRFinal published version, 540 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial'. Together they form a unique fingerprint.

Cite this

Surr, C. A., Walwyn, R. E. A., Lilley-Kelly, A., Cicero, R., Meads, D., Ballard, C., Burton, K., Chenoweth, L., Corbett, A., Creese, B., Downs, M., Farrin, A. J., Fossey, J., Garrod, L., Graham, E. H., Griffiths, A., Holloway, I., Jones, S., Malik, B., ... Wallace, D. (2016). Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. Trials, 17(1), 300. https://doi.org/10.1186/s13063-016-1416-z

@article{d8c0d72c8ccb487288fee876e1aa81b0,

title = "Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping{\texttrademark} to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial",

abstract = "BACKGROUND: Up to 90 % of people living with dementia in care homes experience one or more behaviours that staff may describe as challenging to support (BSC). Of these agitation is the most common and difficult to manage. The presence of agitation is associated with fewer visits from relatives, poorer quality of life and social isolation. It is recommended that agitation is treated through psychosocial interventions. Dementia Care Mapping{\texttrademark} (DCM{\texttrademark}) is an established, widely used observational tool and practice development cycle, for ensuring a systematic approach to providing person-centred care. There is a body of practice-based literature and experience to suggests that DCM{\texttrademark} is potentially effective but limited robust evidence for its effectiveness, and no examination of its cost-effectiveness, as a UK health care intervention. Therefore, a definitive randomised controlled trial (RCT) of DCM{\texttrademark} in the UK is urgently needed.METHODS/DESIGN: A pragmatic, multi-centre, cluster-randomised controlled trial of Dementia Care Mapping (DCM{\texttrademark}) plus Usual Care (UC) versus UC alone, where UC is the normal care delivered within the care home following a minimum level of dementia awareness training. The trial will take place in residential, nursing and dementia-specialist care homes across West Yorkshire, Oxfordshire and London, with residents with dementia. A random sample of 50 care homes will be selected within which a minimum of 750 residents will be registered. Care homes will be randomised in an allocation ratio of 3:2 to receive either intervention or control. Outcome measures will be obtained at 6 and 16 months following randomisation. The primary outcome is agitation as measured by the Cohen-Mansfield Agitation Inventory, at 16 months post randomisation. Key secondary outcomes are other BSC and quality of life. There will be an integral cost-effectiveness analysis and a process evaluation.DISCUSSION: The protocol was refined following a pilot of trial procedures. Changes include replacement of a questionnaire, whose wording caused some residents distress, to an adapted version specifically designed for use in care homes, a change to the randomisation stratification factors, adaption in how the staff measures are collected to encourage greater compliance, and additional reminders to intervention homes of when mapping cycles are due, via text message.TRIAL REGISTRATION: Current Controlled Trials ISRCTN82288852 . Registered on 16 January 2014. Full protocol version and date: v7.1: 18 December 2015.",

author = "Surr, {Claire A} and Walwyn, {Rebecca E A} and Amanda Lilley-Kelly and Robert Cicero and David Meads and Clive Ballard and Kayleigh Burton and Lynn Chenoweth and Anne Corbett and Byron Creese and Murna Downs and Farrin, {Amanda J} and Jane Fossey and Lucy Garrod and Graham, {Elizabeth H} and Alys Griffiths and Ivana Holloway and Sharon Jones and Baber Malik and Najma Siddiqi and Louise Robinson and Graham Stokes and Daphne Wallace",

year = "2016",

month = jun,

day = "24",

doi = "10.1186/s13063-016-1416-z",

language = "English",

volume = "17",

pages = "300",

journal = "Trials",

issn = "1745-6215",

publisher = "BioMed Central",

number = "1",

}

Surr, CA, Walwyn, REA, Lilley-Kelly, A, Cicero, R, Meads, D, Ballard, C, Burton, K, Chenoweth, L, Corbett, A , Creese, B, Downs, M, Farrin, AJ, Fossey, J, Garrod, L, Graham, EH, Griffiths, A, Holloway, I, Jones, S, Malik, B, Siddiqi, N, Robinson, L, Stokes, G & Wallace, D 2016, 'Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial', Trials, vol. 17, no. 1, pp. 300. https://doi.org/10.1186/s13063-016-1416-z

Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. / Surr, Claire A; Walwyn, Rebecca E A; Lilley-Kelly, Amanda et al.
In: Trials, Vol. 17, No. 1, 24.06.2016, p. 300.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes

T2 - study protocol for a randomised controlled trial

AU - Surr, Claire A

AU - Walwyn, Rebecca E A

AU - Lilley-Kelly, Amanda

AU - Cicero, Robert

AU - Meads, David

AU - Ballard, Clive

AU - Burton, Kayleigh

AU - Chenoweth, Lynn

AU - Corbett, Anne

AU - Creese, Byron

AU - Downs, Murna

AU - Farrin, Amanda J

AU - Fossey, Jane

AU - Garrod, Lucy

AU - Graham, Elizabeth H

AU - Griffiths, Alys

AU - Holloway, Ivana

AU - Jones, Sharon

AU - Malik, Baber

AU - Siddiqi, Najma

AU - Robinson, Louise

AU - Stokes, Graham

AU - Wallace, Daphne

PY - 2016/6/24

Y1 - 2016/6/24

N2 - BACKGROUND: Up to 90 % of people living with dementia in care homes experience one or more behaviours that staff may describe as challenging to support (BSC). Of these agitation is the most common and difficult to manage. The presence of agitation is associated with fewer visits from relatives, poorer quality of life and social isolation. It is recommended that agitation is treated through psychosocial interventions. Dementia Care Mapping™ (DCM™) is an established, widely used observational tool and practice development cycle, for ensuring a systematic approach to providing person-centred care. There is a body of practice-based literature and experience to suggests that DCM™ is potentially effective but limited robust evidence for its effectiveness, and no examination of its cost-effectiveness, as a UK health care intervention. Therefore, a definitive randomised controlled trial (RCT) of DCM™ in the UK is urgently needed.METHODS/DESIGN: A pragmatic, multi-centre, cluster-randomised controlled trial of Dementia Care Mapping (DCM™) plus Usual Care (UC) versus UC alone, where UC is the normal care delivered within the care home following a minimum level of dementia awareness training. The trial will take place in residential, nursing and dementia-specialist care homes across West Yorkshire, Oxfordshire and London, with residents with dementia. A random sample of 50 care homes will be selected within which a minimum of 750 residents will be registered. Care homes will be randomised in an allocation ratio of 3:2 to receive either intervention or control. Outcome measures will be obtained at 6 and 16 months following randomisation. The primary outcome is agitation as measured by the Cohen-Mansfield Agitation Inventory, at 16 months post randomisation. Key secondary outcomes are other BSC and quality of life. There will be an integral cost-effectiveness analysis and a process evaluation.DISCUSSION: The protocol was refined following a pilot of trial procedures. Changes include replacement of a questionnaire, whose wording caused some residents distress, to an adapted version specifically designed for use in care homes, a change to the randomisation stratification factors, adaption in how the staff measures are collected to encourage greater compliance, and additional reminders to intervention homes of when mapping cycles are due, via text message.TRIAL REGISTRATION: Current Controlled Trials ISRCTN82288852 . Registered on 16 January 2014. Full protocol version and date: v7.1: 18 December 2015.

AB - BACKGROUND: Up to 90 % of people living with dementia in care homes experience one or more behaviours that staff may describe as challenging to support (BSC). Of these agitation is the most common and difficult to manage. The presence of agitation is associated with fewer visits from relatives, poorer quality of life and social isolation. It is recommended that agitation is treated through psychosocial interventions. Dementia Care Mapping™ (DCM™) is an established, widely used observational tool and practice development cycle, for ensuring a systematic approach to providing person-centred care. There is a body of practice-based literature and experience to suggests that DCM™ is potentially effective but limited robust evidence for its effectiveness, and no examination of its cost-effectiveness, as a UK health care intervention. Therefore, a definitive randomised controlled trial (RCT) of DCM™ in the UK is urgently needed.METHODS/DESIGN: A pragmatic, multi-centre, cluster-randomised controlled trial of Dementia Care Mapping (DCM™) plus Usual Care (UC) versus UC alone, where UC is the normal care delivered within the care home following a minimum level of dementia awareness training. The trial will take place in residential, nursing and dementia-specialist care homes across West Yorkshire, Oxfordshire and London, with residents with dementia. A random sample of 50 care homes will be selected within which a minimum of 750 residents will be registered. Care homes will be randomised in an allocation ratio of 3:2 to receive either intervention or control. Outcome measures will be obtained at 6 and 16 months following randomisation. The primary outcome is agitation as measured by the Cohen-Mansfield Agitation Inventory, at 16 months post randomisation. Key secondary outcomes are other BSC and quality of life. There will be an integral cost-effectiveness analysis and a process evaluation.DISCUSSION: The protocol was refined following a pilot of trial procedures. Changes include replacement of a questionnaire, whose wording caused some residents distress, to an adapted version specifically designed for use in care homes, a change to the randomisation stratification factors, adaption in how the staff measures are collected to encourage greater compliance, and additional reminders to intervention homes of when mapping cycles are due, via text message.TRIAL REGISTRATION: Current Controlled Trials ISRCTN82288852 . Registered on 16 January 2014. Full protocol version and date: v7.1: 18 December 2015.

U2 - 10.1186/s13063-016-1416-z

DO - 10.1186/s13063-016-1416-z

M3 - Article

C2 - 27341812

SN - 1745-6215

VL - 17

SP - 300

JO - Trials

JF - Trials

IS - 1

ER -